The molecular pathogenesis of uterine adenosarcoma (uAS; synonym: Müllerian adenosarcoma) is confounded by its pathologic heterogeneity, with DICER1 mutations and TP53 pathway alterations reported in most tumors with high-grade morphology, stromal overgrowth and/ or rhabdomyoblastic differentiation. However, a small subset of tumors harbor gene fusions, but their molecular spectrum and clinicopathological correlations have not been defined. We identified 12 uAS-like neoplasms in our files carrying ESR1 gene fusions and reviewed 4 previously reported cases (total: 16). Patient's age range was 34 - 76 years (median, 54). The tumors originated in the uterus body (5), unspecified uterus segment (5), cervix (1) and isthmus (1). Follow-up was available for 6 patients (median 44 months, range 9 months-20 years). One patient developed lung metastasis 52 months later and one had an abdominopelvic recurrence > 20 years later. Four patients were disease-free at 9-55 months. All tumors harbored in-frame ESR1 fusions (10 with ESR1::NCOA3, 1 ESR1:NCOA2 and 1 ESR1::MAMLD1). Nine tumors were low-grade and 3 high-grade. All lacked heterologous elements. Stromal overgrowth was recorded in three (all high-grade) and sex cord-like elements in 4 tumors. Phyllodiform architecture, admixed Mullerian glands, and periglandular stromal condensation distinguished the 4 tumors with sex cord-like elements from conventional uterine tumors resembling ovarian sex cord tumor (UTROSCT). This study expands the overlapping morphologic and molecular spectrum of uterine neoplasms resembling uAS showing recurrent fusions (mostly ESR1::NCOA3/2), associated with mostly low-grade histology, lack of heterologous elements and paucity of stromal overgrowth. The nosological relationship of these uAS-like tumors to UTROSCT (driven similarly by ESR1::NCOA3/2 fusions) and to fusion-negative high-grade uAS remains to be verified in future studies utilizing epigenetics and other tools.

Bioptical Laboratory Ltd Plzen Czech Republic

Comprehensive Cancer Center European Metropolitan Area Erlangen Nuremberg Erlangen Germany

Department of Gynecology and Obstetrics Erlangen University Hospital Friedrich Alexander University of Erlangen Nuremberg Erlangen Germany

Department of Pathology and Laboratory Medicine Cleveland Clinic Cleveland OH USA

Department of Pathology and Laboratory Medicine Memorial Sloan Kettering Cancer Center New York NY USA

Department of Pathology and Laboratory Medicine Sinai Health System Toronto ON Canada

Department of Pathology Faculty of Medicine in Plzen Charles University Prague Czech Republic

Department of Pathology Hospital Universitari Arnau de Vilanova University of Lleida CIBERONC Irblleida Spain

Department of Pathology Hospital Universitari de Bellvitge University of Barcelona Idibell Spain

Institute of Pathology Erlangen University Hospital Friedrich Alexander University of Erlangen Nuremberg Erlangen Germany

Laboratory Medicine Program University Health Network Toronto ON Canada

Zobrazit více v PubMed

Ferreira J, Félix A, Lennerz JK, Oliva E (2018) Recent advances in the histological and molecular classification of endometrial stromal neoplasms. Virchows Arch 473:665–678 PubMed DOI

Chiang S, Samore W, Zhang L, Sung YS, Turashvili G, Murali R, Soslow RA, Hensley ML, Swanson D, Dickson BC, Stewart CJR, Oliva E, Antonescu CR (2019) PGR gene fusions identify a molecular subset of uterine epithelioid leiomyosarcoma with rhabdoid features. Am J Surg Pathol 43:810–818 PubMed DOI PMC

.Arias-Stella JA 3rd, Benayed R, Oliva E, Young RH, Hoang LN, Lee CH, Jungbluth AA, Frosina D, Soslow RA, Antonescu CR, Ladanyi M, Chiang S (2019) Novel PLAG1 gene rearrangement distinguishes a subset of uterine myxoid leiomyosarcoma from other uterine myxoid mesenchymal tumors. Am J Surg Pathol 43:382–388

Michal M, Agaimy A, Croce S, Mechtersheimer G, Gross JM, Xing D, Bell DA, Gupta S, Mosaieby E, Martínek P, Klubíčková N, Michalová K, Bouda J, Fínek J, Hernandez T, Michal M, Schoolmeester JK, Ondič O (2024) PLAG1-rearranged uterine sarcomas: a study of 11 cases showing a wide phenotypical spectrum not limited to myxoid leiomyosarcoma-like morphology. Mod Pathol 37:100552 PubMed DOI

Haimes JD, Stewart CJR, Kudlow BA, Culver BP, Meng B, Koay E, Whitehouse A, Cope N, Lee JC, Ng T, McCluggage WG, Lee CH (2017) Uterine inflammatory myofibroblastic tumors frequently harbor ALK fusions with IGFBP5 and THBS1. Am J Surg Pathol 41:773–780 PubMed DOI

Bennett JA, Nardi V, Rouzbahman M, Morales-Oyarvide V, Nielsen GP, Oliva E (2017) Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum. Mod Pathol 30:1489–1503 PubMed DOI

Collins K, Ramalingam P, Euscher ED, Reques Llanos A, García A, Malpica A (2022) Uterine inflammatory myofibroblastic neoplasms with aggressive behavior, including an epithelioid inflammatory myofibroblastic sarcoma: a clinicopathologic study of 9 cases. Am J Surg Pathol 46:105–117 PubMed DOI

Croce S, Hostein I, Longacre TA, Mills AM, Pérot G, Devouassoux-Shisheboran M, Velasco V, Floquet A, Guyon F, Chakiba C, Querleu D, Khalifa E, Mayeur L, Rebier F, Leguellec S, Soubeyran I, McCluggage WG (2019) Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms. Mod Pathol 32:1008–1022 PubMed DOI

Croce S, Hostein I, McCluggage WG (2021) NTRK and other recently described kinase fusion positive uterine sarcomas: a review of a group of rare neoplasms. Genes Chromosomes Cancer 60:147–159 PubMed DOI

Agaimy A, Dermawan JK, Haller F, Semrau S, Meidenbauer N, Stoehr R, Lax S, Hartmann A, Zou YS, Xing D, Tögel L, Gross JM, Michal M (2024) ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity. Virchows Arch 485:805–813 PubMed DOI PMC

Dickson BC, Childs TJ, Colgan TJ, Sung YS, Swanson D, Zhang L, Antonescu CR (2019) Uterine tumor resembling ovarian sex cord tumor: a distinct entity characterized by recurrent NCOA2/3 gene fusions. Am J Surg Pathol 43:178–186 PubMed DOI PMC

Lee CH, Kao YC, Lee WR, Hsiao YW, Lu TP, Chu CY, Lin YJ, Huang HY, Hsieh TH, Liu YR, Liang CW, Chen TW, Yip S, Lum A, Kuo KT, Jeng YM, Yu SC, Chung YC, Lee JC (2019) Clinicopathologic characterization of GREB1-rearranged uterine sarcomas with variable sex-cord differentiation. Am J Surg Pathol 43:928–942 PubMed DOI

Goebel EA, Hernandez Bonilla S, Dong F, Dickson BC, Hoang LN, Hardisson D, Lacambra MD, Lu FI, Fletcher CDM, Crum CP, Antonescu CR, Nucci MR, Kolin DL (2020) Uterine tumor resembling ovarian sex cord tumor (UTROSCT): a morphologic and molecular study of 26 cases confirms recurrent NCOA1-3 rearrangement. Am J Surg Pathol 44:30–42 PubMed DOI PMC

Kao YC, Lee JC (2021) An update of molecular findings in uterine tumor resembling ovarian sex cord tumor and GREB1-rearranged uterine sarcoma with variable sex-cord differentiation. Genes Chromosomes Cancer 60:180–189 PubMed DOI

Agaimy A, Clarke BA, Kolin DL, Lee CH, Lee JC, McCluggage WG, Pöschke P, Stoehr R, Swanson D, Turashvili G, Beckmann MW, Hartmann A, Antonescu CR, Dickson BC (2022) Recurrent KAT6B/A::KANSL1 fusions characterize a potentially aggressive uterine sarcoma morphologically overlapping with low-grade endometrial stromal sarcoma. Am J Surg Pathol 46:1298–1308 PubMed DOI PMC

Trecourt A, Azmani R, Hostein I, Blanchard L, Le Loarer F, Bourdon A, Alame M, Nadaud B, Mayer L, Rebier F, Larmonier C, Moura MS, Soubeyran I, Hartog C, Ray-Coquard I, Treilleux I, Devouassoux-Shisheboran M, Croce S (2023) The KAT6B::KANSL1 fusion defines a new uterine sarcoma with hybrid endometrial stromal tumor and smooth muscle tumor features. Mod Pathol 36:100243 PubMed DOI

Kommoss FKF, Charbel A, Kolin DL, Howitt BE, Köbel M, Lee JC, McCluggage WG, Agaimy A, Dickson BC, von Deimling A, Lee CH (2024) Uterine mesenchymal tumours harboring the KAT6B/A::KANSL1 gene fusion represent a distinct type of uterine sarcoma based on DNA methylation profiles. Virchows Arch 485:793–803 PubMed DOI PMC

Dundr P, Dvořák J, Krausová M, Hojný J, Hájková N, Stružinská I, Němejcová K, Ondič O, Michal M, Michalová K, Berjón A, Jedryka M, Książek M, Poprawski T, Ryś J, Volodko N, Zapardiel I, Zima T, Cibula D, Poncová R, Matěj R, Kendall Bártů M (2025) Uterine sarcoma with KAT6B/A::KANSL1 fusion: a molecular and clinicopathological study on 9 cases. Virchows Arch 486:551–562 PubMed DOI

Clement PB, Scully RE (1974) Müllerian adenosarcoma of the uterus: a clinicopathologic analysis of ten cases of a distinctive type of müllerian mixed tumor. Cancer 34:1138–1149 PubMed DOI

Gallardo A, Prat J (2009) Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol 33:278–288 PubMed DOI

Tanner EJ, Toussaint T, Leitao MM Jr et al (2013) Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecol Oncol 129(1):140–144 PubMed DOI

Ban Y, Fischer JV, Maniar KP, Guo H, Zeng C, Li Y, Zhang Q, Wang X, Zhang W, Bulun SE, Wei JJ (2020) Whole-genome sequencing and target validation analysis of Mullerian adenosarcoma: a tumor with complex but specific genetic alterations. Front Oncol 10:538 PubMed DOI PMC

Howitt BE, Sholl LM, Dal Cin P, Jia Y, Yuan L, MacConaill L, Lindeman N, Kuo F, Garcia E, Nucci MR, Quade BJ (2015) Targeted genomic analysis of Müllerian adenosarcoma. J Pathol 235:37–49 PubMed DOI

Piscuoglio S, Burke KA, Ng CK, Papanastasiou AD, Geyer FC, Macedo GS, Martelotto LG, de Bruijn I, De Filippo MR, Schultheis AM, Ioris RA, Levine DA, Soslow RA, Rubin BP, Reis-Filho JS, Weigelt B (2016) Uterine adenosarcomas are mesenchymal neoplasms. J Pathol 238:381–388 PubMed DOI

Yuan CT, Huang WC, Lee CH, Lin MC, Lee CH, Kao YC, Huang HY, Kuo KT, Lee JC (2017) Comprehensive screening for MED12 mutations in gynaecological mesenchymal tumours identified morphologically distinctive mixed epithelial and stromal tumours. Histopathology 70:954–965 PubMed DOI

Hodgson A, Amemiya Y, Seth A, Djordjevic B, Parra-Herran C (2017) High-grade mullerian adenosarcoma: genomic and clinicopathologic characterization of a distinct neoplasm with prevalent TP53 pathway alterations and aggressive behavior. Am J Surg Pathol 41:1513–1522 PubMed DOI

Bean GR, Anderson J, Sangoi AR, Krings G, Garg K (2019) DICER1 mutations are frequent in mullerian adenosarcomas and are independent of rhabdomyosarcomatous differentiation. Mod Pathol 32(2):280–289 PubMed DOI

Momeni Boroujeni A, Kertowidjojo E, Wu X, Soslow RA, Chiang S, Da Silva EM, Weigelt B, Chui MH (2022) Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors. Mod Pathol 35:1684–1694 PubMed DOI

Apellaniz-Ruiz M, McCluggage WG, Foulkes WD (2021) DICER1-associated embryonal rhabdomyosarcoma and adenosarcoma of the gynecologic tract: pathology, molecular genetics, and indications for molecular testing. Genes Chromosomes Cancer 60:217–233 PubMed DOI

Li Y, Meng X, Luo Y, Huang X, Luo S, Wang J (2023) Next-generation sequencing analysis of 3 uterine adenosarcomas with heterogeneously differentiated genomic mutations. Int J Anal Chem 2023:7436368 PubMed DOI PMC

Muthukumarana V, Fix DJ, Stolnicu S, Park KJ, Soslow RA, Benayed R, Ladanyi M, Antonescu CR, Chiang S (2020) Bcor expression in Mullerian adenosarcoma: a potential diagnostic pitfall. Am J Surg Pathol 44:765–770 PubMed DOI PMC

Hasegawa C, Washimi K, Hiroshima Y, Kasajima R, Kikuchi K, Notomi T, Kato H, Hiruma T, Sato S, Okubo Y, Yoshioka E, Ono K, Miyagi Y, Yokose T (2023) Differential diagnosis of uterine adenosarcoma: identification of JAZF1-BCORL1 rearrangement by comprehensive cancer genomic profiling. Diagn Pathol 18:5 PubMed DOI PMC

Rabban JT, Devine WP, Sangoi AR, Poder L, Alvarez E, Davis JL, Rudzinski E, Garg K, Bean GR (2020) NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma. Histopathology 77:100–111 PubMed DOI

Lin DI, Allen JM, Hecht JL, Killian JK, Ngo NT, Edgerly C, Severson EA, Ali SM, Erlich RL, Ramkissoon SH, Vergilio JA, Ross JS, Elvin JA (2019) SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association. Mod Pathol 32:1675–1687 PubMed DOI

Warmke LM, Michal M, Martínek P, Agaimy A, Din NU, Perret R, Hostein I, Le Loarer F, Voltaggio L, Gross JM (2023) PRRX1-rearranged mesenchymal tumors": expanding the immunohistochemical profile and molecular spectrum of a recently described entity with the proposed revision of nomenclature. Virchows Arch 483(2):207–214 PubMed DOI

Zhu G, Benayed R, Ho C, Mullaney K, Sukhadia P, Rios K, Berry R, Rubin BP, Nafa K, Wang L, Klimstra DS, Ladanyi M, Hameed MR (2019) Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Mod Pathol 32(5):609–620 PubMed DOI

Lin DI, Huang RSP, Mata DA, Decker B, Danziger N, Lechpammer M, Hiemenz M, Ramkissoon SH, Ross JS, Elvin JA (2021) Clinicopathological and genomic characterization of BCORL1-driven high-grade endometrial stromal sarcomas. Mod Pathol 34:2200–2210 PubMed DOI

Kommoss FKF, Chiang S, Köbel M, Koelsche C, Chang KT, Irving JA, Dickson B, Thiryayi S, Rouzbahman M, Rasty G, von Deimling A, Lee CH, Turashvili G (2022) Endometrial stromal sarcomas with BCOR internal tandem duplication and variant BCOR/BCORL1 rearrangements resemble high-grade endometrial stromal sarcomas with recurrent CDK4 pathway alterations and MDM2 amplifications. Am J Surg Pathol 46:1142–1152 PubMed DOI

Moghaddam PA, Young RH, Ismiil ND, Bennett JA, Oliva E (2024) An unusual endometrial stromal neoplasm with JAZF1-BCORL1 rearrangement. Int J Gynecol Pathol 43:33–40 PubMed DOI

Rodriguez Pena MDC, Mubeen A, Harada S, Prieto Granada CN (2023) An unusual benign uterine stromal spindle cell tumor harboring JAZF1::BCORL1. Int J Gynecol Pathol 42:319–324 PubMed DOI

Ribeiro E, Ribeiro R, Lewin ER, Hart JL, Quddus MR, Hansen K (2022) Primary fallopian tube Mullerian adenosarcoma with sarcomatous overgrowth and a previously unreported MEIS1-NCOA2 gene fusion. Int J Gynecol Pathol 41:82–85 DOI

Kao YC, Bennett JA, Suurmeijer AJH, Dickson BC, Swanson D, Wanjari P, Zhang L, Lee JC, Antonescu CR (2021) Recurrent MEIS1-NCOA2/1 fusions in a subset of low-grade spindle cell sarcomas frequently involving the genitourinary and gynecologic tracts. Mod Pathol 34:1203–1212 PubMed DOI PMC